Ray Dalio's REGN Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 72,745 shares of Regeneron Pharmaceuticals, Inc. (REGN) worth $56.15 M, representing 0.20% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 40 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in REGN, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 146,334 shares. Largest reduction occurred in Q4 2025, reducing 162,636 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Regeneron Pharmaceuticals (REGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Regeneron Pharmaceuticals (REGN) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -162,636 | Reduce 69.09% | 72,745 | $771.87 |
| Q3 2025 | +146,334 | Add 164.33% | 235,381 | $562.27 |
| Q2 2025 | +68,056 | Add 324.22% | 89,047 | $525.00 |
| Q1 2025 | +20,702 | Add 7163.32% | 20,991 | $634.23 |
| Q4 2024 | -268 | Reduce 48.11% | 289 | $712.33 |
| Q3 2024 | -4,797 | Reduce 89.60% | 557 | $1051.24 |
| Q2 2024 | -55,792 | Reduce 91.24% | 5,354 | $1051.03 |
| Q1 2024 | -48,986 | Reduce 44.48% | 61,146 | $962.49 |
| Q4 2023 | +49,383 | Add 81.29% | 110,132 | $878.29 |
| Q3 2023 | -40,184 | Reduce 39.81% | 60,749 | $822.96 |
| Q2 2023 | +36,035 | Add 55.53% | 100,933 | $718.54 |
| Q1 2023 | +26,017 | Add 66.91% | 64,898 | $821.67 |
| Q4 2022 | -18,596 | Reduce 32.35% | 38,881 | $721.49 |
| Q3 2022 | -16,423 | Reduce 22.22% | 57,477 | $688.87 |
| Q2 2022 | +68,448 | Add 1255.47% | 73,900 | $591.14 |
| Q1 2022 | -2,083 | Reduce 27.64% | 5,452 | $698.46 |
| Q4 2021 | +113 | Add 1.52% | 7,535 | $631.59 |
| Q3 2021 | -5,263 | Reduce 41.49% | 7,422 | $605.23 |
| Q2 2021 | +12,685 | New Buy | 12,685 | $558.53 |
| Q4 2019 | -61,705 | Sold Out | 0 | $0.00 |
| Q3 2019 | +59,330 | Add 2498.11% | 61,705 | $277.40 |
| Q2 2019 | +2,375 | New Buy | 2,375 | $312.84 |
| Q1 2019 | -4,842 | Sold Out | 0 | $0.00 |
| Q4 2018 | -7,930 | Reduce 62.09% | 4,842 | $373.40 |
| Q3 2018 | +1,273 | Add 11.07% | 12,772 | $404.01 |
| Q2 2018 | -10,373 | Reduce 47.43% | 11,499 | $344.99 |
| Q1 2018 | +21,872 | New Buy | 21,872 | $344.37 |
| Q4 2017 | -25,700 | Sold Out | 0 | $0.00 |
| Q3 2017 | +25,700 | New Buy | 25,700 | $447.12 |
| Q2 2016 | -900 | Sold Out | 0 | $0.00 |
| Q1 2016 | +900 | New Buy | 900 | $360.00 |
| Q4 2015 | -1,800 | Sold Out | 0 | $0.00 |
| Q3 2015 | +1,000 | Add 125.00% | 1,800 | $465.00 |
| Q2 2015 | +800 | New Buy | 800 | $510.00 |
| Q1 2015 | -11,800 | Sold Out | 0 | $0.00 |
| Q4 2014 | +10,200 | Add 637.50% | 11,800 | $410.25 |
| Q3 2014 | -16,800 | Reduce 91.30% | 1,600 | $360.62 |
| Q2 2014 | +18,400 | New Buy | 18,400 | $282.45 |
| Q3 2013 | -4,100 | Sold Out | 0 | $0.00 |
| Q2 2013 | +4,100 | Add 0.00% | 4,100 | $224.88 |
Ray Dalio's Regeneron Pharmaceuticals Investment FAQs
Ray Dalio first purchased Regeneron Pharmaceuticals, Inc. (REGN) in Q2 2013, acquiring 4,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Regeneron Pharmaceuticals, Inc. (REGN) for 40 quarters since Q2 2013.
Ray Dalio's largest addition to Regeneron Pharmaceuticals, Inc. (REGN) was in Q3 2025, adding 235,381 shares worth $132.35 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 72,745 shares of Regeneron Pharmaceuticals, Inc. (REGN), valued at approximately $56.15 M.
As of the Q4 2025 filing, Regeneron Pharmaceuticals, Inc. (REGN) represents approximately 0.20% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Regeneron Pharmaceuticals, Inc. (REGN) was 235,381 shares, as reported at the end of Q3 2025.